Summary

Oral Solid Dosage Pharmaceutical Formulation Market – Scope of Report
TMR’s report on the global oral solid dosage pharmaceutical formulation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global oral solid dosage pharmaceutical formulation market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oral solid dosage pharmaceutical formulation market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the oral solid dosage pharmaceutical formulation market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oral solid dosage pharmaceutical formulation market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oral solid dosage pharmaceutical formulation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oral solid dosage pharmaceutical formulation market.

The report delves into the competitive landscape of the global oral solid dosage pharmaceutical formulation market. Key players operating in the global oral solid dosage pharmaceutical formulation market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oral solid dosage pharmaceutical formulation market profiled in this report.

Key Questions Answered in Global oral solid dosage pharmaceutical formulation Market Report
• What is the sales/revenue generated by oral solid dosage pharmaceutical formulation across all regions during the forecast period?
• What are the opportunities in the global oral solid dosage pharmaceutical formulation market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Oral Solid Dosage Pharmaceutical Formulation Market – Research Objectives and Research Approach
The comprehensive report on the global oral solid dosage pharmaceutical formulation market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oral solid dosage pharmaceutical formulation market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oral solid dosage pharmaceutical formulation market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Oral Solid Dosage Pharmaceutical Formulation Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product /Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Dosage Form
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Dosage Form, 2020-2034
        6.3.1. Tablets
            6.3.1.1. Conventional/Immediate Release
            6.3.1.2. Modified Release
            6.3.1.3. Chewable Tablets
            6.3.1.4. Effervescent Tablets
        6.3.2. Capsules
            6.3.2.1. Hard Gelatin Capsules
            6.3.2.2. Soft Gelatin Capsules
        6.3.3. Powders
        6.3.4. Lozenges & Pastilles
        6.3.5. Gummies
    6.4. Market Attractiveness Analysis, by Dosage Form
7. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Drug Release Mechanism
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Drug Release Mechanism, 2020-2034
        7.3.1. Immediate Release
        7.3.2. Delayed Release
        7.3.3. Controlled Release
    7.4. Market Attractiveness Analysis, by Drug Release Mechanism
8. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2020-2034
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2020-2034
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Dosage Form, 2020-2034
        10.3.1. Tablets
            10.3.1.1. Conventional/Immediate Release
            10.3.1.2. Modified Release
            10.3.1.3. Chewable Tablets
            10.3.1.4. Effervescent Tablets
        10.3.2. Capsules
            10.3.2.1. Hard Gelatin Capsules
            10.3.2.2. Soft Gelatin Capsules
        10.3.3. Powders
        10.3.4. Lozenges & Pastilles
        10.3.5. Gummies
    10.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
        10.4.1. Immediate Release
        10.4.2. Delayed Release
        10.4.3. Controlled Release
    10.5. Market Value Forecast, by Distribution Channel, 2020-2034
        10.5.1. Hospital Pharmacies
        10.5.2. Retail Pharmacies
        10.5.3. Online Pharmacies
    10.6. Market Value Forecast, by Country, 2020-2034
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Dosage Form
        10.7.2. By Drug Release Mechanism
        10.7.3. By Distribution Channel
        10.7.4. By Country
11. Europe Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Dosage Form, 2020-2034
        11.3.1. Tablets
            11.3.1.1. Conventional/Immediate Release
            11.3.1.2. Modified Release
            11.3.1.3. Chewable Tablets
            11.3.1.4. Effervescent Tablets
        11.3.2. Capsules
            11.3.2.1. Hard Gelatin Capsules
            11.3.2.2. Soft Gelatin Capsules
        11.3.3. Powders
        11.3.4. Lozenges & Pastilles
        11.3.5. Gummies
    11.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
        11.4.1. Immediate Release
        11.4.2. Delayed Release
        11.4.3. Controlled Release
    11.5. Market Value Forecast, by Distribution Channel, 2020-2034
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Dosage Form
        11.7.2. By Drug Release Mechanism
        11.7.3. By Distribution Channel
        11.7.4. By Country/Sub-region
12. Asia Pacific Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Dosage Form, 2020-2034
        12.3.1. Tablets
            12.3.1.1. Conventional/Immediate Release
            12.3.1.2. Modified Release
            12.3.1.3. Chewable Tablets
            12.3.1.4. Effervescent Tablets
        12.3.2. Capsules
            12.3.2.1. Hard Gelatin Capsules
            12.3.2.2. Soft Gelatin Capsules
        12.3.3. Powders
        12.3.4. Lozenges & Pastilles
        12.3.5. Gummies
    12.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
        12.4.1. Immediate Release
        12.4.2. Delayed Release
        12.4.3. Controlled Release
    12.5. Market Value Forecast, by Distribution Channel, 2020-2034
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Dosage Form
        12.7.2. By Drug Release Mechanism
        12.7.3. By Distribution Channel
        12.7.4. By Country/Sub-region
13. Latin America Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Dosage Form, 2020-2034
        13.3.1. Tablets
            13.3.1.1. Conventional/Immediate Release
            13.3.1.2. Modified Release
            13.3.1.3. Chewable Tablets
            13.3.1.4. Effervescent Tablets
        13.3.2. Capsules
            13.3.2.1. Hard Gelatin Capsules
            13.3.2.2. Soft Gelatin Capsules
        13.3.3. Powders
        13.3.4. Lozenges & Pastilles
        13.3.5. Gummies
    13.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
        13.4.1. Immediate Release
        13.4.2. Delayed Release
        13.4.3. Controlled Release
    13.5. Market Value Forecast, by Distribution Channel, 2020-2034
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Dosage Form
        13.7.2. By Drug Release Mechanism
        13.7.3. By Distribution Channel
        13.7.4. By Country/Sub-region
14. Middle East & Africa Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Dosage Form, 2020-2034
        14.3.1. Tablets
            14.3.1.1. Conventional/Immediate Release
            14.3.1.2. Modified Release
            14.3.1.3. Chewable Tablets
            14.3.1.4. Effervescent Tablets
        14.3.2. Capsules
            14.3.2.1. Hard Gelatin Capsules
            14.3.2.2. Soft Gelatin Capsules
        14.3.3. Powders
        14.3.4. Lozenges & Pastilles
        14.3.5. Gummies
    14.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
        14.4.1. Immediate Release
        14.4.2. Delayed Release
        14.4.3. Controlled Release
    14.5. Market Value Forecast, by Distribution Channel, 2020-2034
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Dosage Form
        14.7.2. By Drug Release Mechanism
        14.7.3. By Distribution Channel
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2023)
    15.3. Company Profiles
        15.3.1. AstraZeneca plc
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Bristol-Myers Squibb Company
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. Eli Lilly and Company
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Gilead Sciences, Inc.
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Merck & Co. Inc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Novartis AG
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Pfizer Inc.
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. AbbVie Inc.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Boehringer Ingelheim GmbH
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. F. Hoffmann-La Roche Ltd.
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview
        15.3.11. Johnson & Johnson
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Financial Overview
            15.3.11.5. Strategic Overview
        15.3.12. Biogen Inc.
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Financial Overview
            15.3.12.5. Strategic Overview
        15.3.13. Bayer AG
            15.3.13.1. Company Overview
            15.3.13.2. Product Portfolio
            15.3.13.3. SWOT Analysis
            15.3.13.4. Financial Overview
            15.3.13.5. Strategic Overview
        15.3.14. Teva Pharmaceutical Industries Ltd.
            15.3.14.1. Company Overview
            15.3.14.2. Product Portfolio
            15.3.14.3. SWOT Analysis
            15.3.14.4. Financial Overview
            15.3.14.5. Strategic Overview
        15.3.15. Amgen Inc.
            15.3.15.1. Company Overview
            15.3.15.2. Product Portfolio
            15.3.15.3. SWOT Analysis
            15.3.15.4. Financial Overview
            15.3.15.5. Strategic Overview
        15.3.16. Takeda Pharmaceutical Company
            15.3.16.1. Company Overview
            15.3.16.2. Product Portfolio
            15.3.16.3. SWOT Analysis
            15.3.16.4. Financial Overview
            15.3.16.5. Strategic Overview
        15.3.17. Otsuka Pharmaceutical Co., Ltd.
            15.3.17.1. Company Overview
            15.3.17.2. Product Portfolio
            15.3.17.3. SWOT Analysis
            15.3.17.4. Financial Overview
            15.3.17.5. Strategic Overview